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Abstract Mammotropic hormones and growth factors play a
very important role in mammary growth and differentiation.
Here, hormones including Estrogen, Progesterone, Prolactin,
their cognate receptors, and the growth factor Amphiregulin,
are tested with respect to their roles in signaling non-
mammary cells from the mouse to redirect to mammary epi-
thelial cell fate(s). This was done in the context of glandular
regeneration in pubertal athymic female mice. Our previous
studies demonstrated that mammary stem cell niches are reca-
pitulated during gland regeneration in vivo. During this pro-
cess, cells of exogenous origin cooperate with mammary ep-
ithelial cells to form mammary stem cell niches and thus re-
spond to normal developmental signals. In all cases tested
with the possible exception of estrogen receptor alpha
(ER-α), hormone signaling is dispensable for non-mammary
cells to undertake mammary epithelial cell fate(s), proliferate,
and contribute progeny to chimeric mammary outgrowths.
Importantly, redirected non-mammary cell progeny, regard-
less of their source, have the ability to self-renew and contrib-
ute offspring to secondary mammary outgrowths derived from
transplanted chimeric mammary fragments; thus suggesting
that some of these cells are capable of mammary stem cell/
progenitor functions.
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Schofield first postulated the concept of the stem cell
niche as a specific location that supported and maintained
hematopoietic stem cell function [1]. The theory was pro-
posed to explain why cells isolated from aged mice were
as capable of long-term engraftment in young recipients as
hematopoietic stem cells isolated from young donors.
Schofield postulated that the stem cells were essentially
immortal as long as they resided in the niche [1]. In this
way, Schofield’s model fits well with our understanding of
mammary gland stem cell function.
One intriguing aspect of Schofield’s theory was that cells
other than the native stem cells (e.g. slightly more mature
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descendants of the stem cell) could function as normal stem
cells when placed into the correct niche [1]. This hypothesis
was put to the test in the mammary gland by combining stem/
progenitor cells from non-mammary tissues with normal dif-
ferentiated mammary epithelial cells (MEC) during transplan-
tation into a gland-free fat pad (Reviewed in [2]). In the initial
experiments, cells isolated from the seminiferous tubules of
male WapCre/Rosa26-lacZ (WC/R26-lacZ+) mice were inoc-
ulated into the gland-free fat pads of Nu/Nu mice in a 1:1 ratio
(50,000:50,000 cells) with normal mouseMEC [3]. Following
pregnancy and involution, WC/R26-lacZ+ cells were seen
throughout the epithelial tree. By using the WC/R26-lacZ
model, it was demonstrated that the testicular cells had
not only contributed to the formation of ducts and lobules,
but had activated the WAP promoter during pregnancy and
survived involution (i.e. had functioned as parity identified
mammary epithelial cells (PI-MEC)) [3, 4]. Furthermore,
the WC/R26-lacZ+ cells were shown by immune-
fluorescence to differentiate into luminal and basal cells,
including cells that produced milk proteins during lactation,
and contributed to second-generation outgrowths upon
transplantation.
In a follow-up experiment, isolated neuronal stem cells
(NSC) from male WC/R26-lacZ+ mice were utilized in lieu
of the cells isolated from the seminiferous tubules and were
found also to contribute to mammary gland regeneration [5].
Interestingly, it was shown that in second generation out-
growths generated from the NSC/MEC chimeric glands some
WC/R26-lacZ+ cells retained expression of the NSC markers
nestin and Sox2. In normal mammary outgrowths, Sox2 was
not detected and nestin was expressed in a much smaller pop-
ulation of cells. Despite the presence of these markers in
second-generation outgrowths, NSC that displayed differenti-
ation potential similar to that of the parental population could
not be recovered. This demonstrates that the NSC, while
functioning as mammary stem/progenitor cells, retained
some of the properties of normal NSC. These results
demonstrate that a strict epitope surface expression pattern
is not required for stem/progenitor cell function and
underscore potential pit-falls in defining cells in this way.
Further, Streuli and colleagues demonstrated by genetic
knockout that the purported mammary stem cell marker
CD49f (α-6 integrin) is dispensable in mammary gland
development [6]. Thus, the ability of a cell to function
as a stem cell does not appear to be defined by its surface
integrin expression.
Recent work has shown that the mouse mammary gland
can redirect non-mammary cell to undertake mammary epi-
thelial cell fates [3, 7–9] (Fig. 1). It is clear from these studies
that mammary epithelial signals as well as those from the
mammary stroma are required. Here, we review whether
mammotropic hormones and growth factors are required for
this activity.
Estrogen
Estrogen Production and Signaling
Estrogens are the primary female sex hormone in vertebrates
and responsible for growth of a number of tissues including
those of the mammary gland. Three naturally occurring forms
of estrogen, including estrone, estradiol, and estriol are mainly
produced by the ovaries and regulated by the release of go-
nadotropins [10]. Of the three estrogens, estradiol is the most
abundant and well studied. While most estrogen originates
from the ovaries, a number of other tissues and cell types also
produce estrogen including cells of adipose tissue, bone,
blood vessel endothelium, and aortic smooth muscle [11].
Estrogens are produced by the enzymatic activity of aromatase
from the precursor androgen forms [12].
Estrogens have two cognate receptors in cells, estrogen
receptor alpha and beta (ERα, ERβ). Signaling of the
estrogen-receptor complex occurs in two pathways, the clas-
sical genomic, in which the complex binds to estrogen re-
sponse elements in the promoters of target gene, or the non-
genomic pathway, in which the estrogen-ER complex binds
with other protein partners including AP-1 and SF-1 to mod-
ulate gene transcription [13]. The majority of estrogen recep-
tor proteins are located in the cell cytoplasm. During classical
genomic signaling, binding of estrogens to their receptors
leads to translocation of the complex from the cytoplasm to
the cell’s nucleus [13]. In addition, estrogen receptors can also
associate with the cell membrane via a palmitic group and
interact with membrane g-protein coupled receptors [14].
These membrane associated estrogen receptors lack signaling
capability but rather recruit scaffolding proteins to activate the
PI3K and MAPK signaling pathways [14]. Thus, estrogen
signaling can occur in a single cell via multiple mechanisms
leading to a highly coordinated cellular process controlling
cellular proliferation and differentiation.
Estrogen in the Mammary Gland
Predominant growth of the mammalian mammary gland oc-
curs after birth at puberty during which luminal epithelial cells
surrounded by basal cells, including myoepithelial cells, form
ducts in which future milk will be transported. Formation of
these ducts is coordinated by estradiol and estrogen receptor
alpha (ERα) [15]. Disruption of the estrogen receptor gene in
mice demonstrated a deficiency in post-pubertal ductal elon-
gation and terminal end bud formation however pre-pubertal
growth of the primitive epithelial rudiment was unaffected
[15]. Interestingly ablation of the ERβ gene did not alter duc-
tal elongation but did affect terminal differentiation of mam-
mary epithelium in those mice [16]. Thus these results indicate
that ERα expression in the mammary gland is necessary for
post-pubertal ductal growth.
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The mammary microenvironment is made up of epithelial
cells that provide the architecture of the ducts and later acinar
and lobular structures but is predominately composed of stro-
mal cells including fibroblasts and adipose cells. Numerous
studies have sought to determine whether ER is necessary in
the epithelial component, the stromal component, or both for
hormonally dependent organ development [17]. In such stud-
ies, the use of ERαknock out mice (ERαKO) provided for
four combinations to elucidate whether ERα was a necessary
stromal or epithelial component for growth [17]. Such combi-
nations included wild type (WT) stroma or epithelium with
knock out (KO) stroma or epithelium leading to the following
WT-S + WT-E, WT-S + KO-E, KO-S + WT-E, and KO-S +
KO-E [17]. While studies on uterine epithelium development
indicated that ERα was necessary in the stroma and not in the
epithelium, these findings were complicated by the fact that
the ERαKO mice still expressed a truncated ERα protein that
contained transactivation activity [17, 18]. Later using a dif-
ferent ERαKO model mouse in which no form of ERα was
detected, it was confirmed that ERα expression in the epithe-
lium, not the stroma, is necessary for mammary gland devel-
opment post-puberty [18].
Estrogen and Mammary Stem Cells
Mammary gland development is a cyclical phenomenon char-
acterized by rapid growth and differentiation during pregnan-
cy followed by involution and later regrowth during subse-
quent pregnancies. Further, transplantation of fragments from
these glands into fat pads divested of epithelium in mice leads
to full growth of a functional mammary gland [19]. Taken
together this evidence supports the presence of a mammary
stem cell population that is maintained post-puberty. A func-
tional characteristic of a stem cell is that it is pluripotent, or
able to give rise to many different cell types from a single cell,
however molecular characterization of the mammary stem cell
population remains contested. Previously, we have shown
using mouse mammary tumor virus infection of CzechII mice
that a single mammary stem cell with a unique viral insertion
can give rise to progeny composing an entire mammary gland.
This observation was the first compelling evidence for the
existence of a mammary cell capable of generating all of the
epithelial subtypes present in a fully functional glandular out-
growth [20].
While these experiments demonstrate that indeed a stem
cell population likely exists in the mammary gland, the ex-
pression of hormone receptors including ER in cells with stem
cell function remains controversial. Evidence of conflicting
roles for estrogen signaling in mammary stem cells exists.
The first being that ER expressing cells represent a hormone
sensing, differentiated cell population that acts through a para-
crine function to modulate mammary gland growth. Indeed, in
ovariectomized mice in which circulating endocrine levels of
estrogen are depleted, the number of repopulating
CD29h iCD24+ is unal tered whereas the luminal
CD29loCD24+ population is greatly reduced, indicating that
estrogen likely does not act directly on the stem cell popula-
tion but rather as a paracrine factor necessary for luminal cell
proliferation [21]. The CD29hiCD24+ population does not ex-
press ERα and chimeric outgrowths produced from a mixture
of WTand ERα- cells rescue the ERαKO phenotype and lead
to full mammary gland development [18, 20].
The second proposed mechanism is based on the hallmark
stem cell function of protecting their genome from mutation
and cancer risk through asymmetric cell division and selective
segregation of their template DNA [22]. Under this principal,
mammary stem cells are likely kept in a slow or non-cycling
state and give rise to a transit amplifying or differentiated
Fig. 1 Repopulation of a stem
cell niche by non-mammary cells.
Diagram illustrates the process of
normal (left side) mammary niche
dissociation and repopulation
(right side) during gland
regeneration in vivo. Empty
niches are illustrated with non-
mammary stem/progenitor cells
incorporated into reforming
mammary niches (right side).
These niches then signal the
exogenous progenitor
populations to behave as
multipotent mammary cells,
resulting in both myoepithelial
and luminal cell progeny
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daughter cell population. Previously, we have shown that
mouse mammary cells undergo asymmetric division in which
parental cells retain DNA labeled with [3H]-thymidine while
daughter cells inherit newly synthesized strands [23]. These
label-retaining epithelial cells (LRECs) comprised 2 % of the
mammary epithelium and Immunohistochemical staining
demonstrated that 30–40 % of the LREC population was pos-
itive for ERα or progesterone receptor (PR) [24]. Similarly,
using radiolabelling of human breast tissue implanted into
mice, LRECs present in outgrowths were enriched for the
stem cell markers p21 (CIP1) and Musashi-1 (Msi-1) and
expressed the hormone receptors ERα and PR [25]. These
findings support early observations that the highly proliferat-
ing cell populations of the mouse mammary gland along the
ducts and terminal end buds are predominately ER- and that in
normal human breast tissue, ER+ cells do not express high
levels of the proliferation antigen Ki67 [25, 26].
Estrogen-Amphiregulin Axis in Mammary Stem Cells
Binding and activation of estrogen to the ER leads to tran-
scription of target genes, including the growth factor
amphiregulin (AREG). AREG is a member of the epidermal
growth factor family induced by estrogen, and like ER is nec-
essary in the mammary epithelium for cell proliferation, TEB
formation, and ductal elongation. AREG null mouse mamma-
ry cells phenocopy ERαKO cells in that they form only small
rudimentary ducts and this limited growth characteristic is
maintained in transplantation studies [27]. However, AREG
null mouse mammary glands still undergo alveologenesis and
lactogenesis during pregnancy [28]. AREG is secreted as a
pre-protein that is cleaved by the transmembrane metallopro-
teinase ADAM17 and then binds to EGFR to induce epithelial
cell proliferation. Adam17 null fragment outgrowths also
demonstrate limited expansion but can be rescued by local
AREG administration [29]. Similarly using siRNA to knock-
down AREG expression, we have demonstrated that AREG is
necessary for mammosphere formation of COMMA-D β-geo
cells via MAPK signaling in vitro [30]. Chimeric studies have
demonstrated that AREG null (AREGKO) cells when mixed
with wild-type cells produce full outgrowths similar to those
observed in ERαKO studies [27].
Progesterone
Progesterone and Mammary Gland Development
Progesterone (P) is fundamentally important for lobular devel-
opment and acts through its nuclear receptor (PR), which is
synthesized in response to estrogen. In the mammary gland,
two isoforms of PR (PR-A and PR-B) have been identified
whose transcription from a single gene is regulated by two
alternative promoters [31–33].
Further analysis revealed that of the two isoforms only PR-
B is required for mammary gland development [32, 34]. Like
ERα, PR is expressed in both epithelial and stromal compart-
ments in the mouse mammary gland [35, 36].
PR knockout (PRKO) mice have shown that progesterone
signaling is necessary for mammary side branching and
alveologenesis during mammary gland development
[37–39]. PRKO mice were made and described in [38]. In
these mice, the PR gene is deleted by the insertion of the LacZ
transgene under the control of the PR promoter [38]. Mam-
mary epithelial cells that carry homozygous deletion of the PR
gene can be identified by the expression of the nuclear local-
ized Beta-Galactosidase (β-Gal) enzyme encoded by the LacZ
gene. In PRKO mice, mammary glands are characterized by
robust ductal structures resembling those of a wild type (WT)
virgin; yet they do not respond to pregnancy hormones by
producing side branches, developing alveoli, or producing
milk [39]. PR-LacZ+ cells were found at the distal tips of side
branches during early pregnancy but not during late pregnan-
cy and lactation suggesting that progesterone signaling is im-
portant during early pregnancy to stimulate side branching
and alveologenesis [38].
The significant impairment of PRKO mammary glands
identified during pregnancy confirmed the necessity of pro-
gesterone signaling in pregnancy mammogenesis [39]. We
can therefore conclude that inherent epithelial PR signaling
is required for side branching and alveologenesis. Other stud-
ies suggested that PR expression in the stroma may be neces-
sary for complete ductal expansion development [40]. Wnt4,
Msx2, and receptor of activated NF-κB ligand (RANKL) are
downstream mediators of progesterone signaling and over-
expression of these proteins leads to an unexpected increase
in ductal side branching and/or lobular development [41–43].
Recent studies have shown that the interaction of PRKO
cells with WT mammary cells is sufficient to restore side
branching and alveologenesis indicating that like ERα signal-
ing, PR can function through a paracrine mechanism during
pubertal development, peaking at 8 weeks and localized to the
body cells of the TEB’s and luminal cells of ducts [44]. Fur-
ther studies concluded that theWnt pathway plays an essential
role in mediating progesterone function during pregnancy
[45].
PR and Non-Mammary Stem Cells
The role of progesterone signaling in non-mammary stem/
progenitor populations can be examined by utilizing cell
mixing experiments and transplantation into cleared fat pads
of host mice. To determine if PRKO MEC were capable of
redirecting non-mammary cells in the absence of PR signal-
ing, we mixed in a 1:1 ratio WT testicular cells with PRKO-
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LacZ MECs isolated from homozygous PRKO mice that
expressed β-Gal under the PR promoter activation [46]. The
mixed cell population was then inoculated into cleared fat
pads of pubertal athymic nude mice. When testicular cells
where inoculated alone in the cleared fat pad failed to grow
[46]. However, PRKO-LacZ MECs grew but failed to under-
go complete lobular development [46]. When testicular cells
were mixed with PRKO-LacZ MEC, some of the resulting
outgrowths demonstrated increased alveolar formation [46].
Our results demonstrate that PR expression is not required to
redirect WT testicular cells to mammary cell fates including
secretory development, and further that the reprogrammed
testis-derived cells were capable of supporting lobular devel-
opment in the PRKO epithelium [46]. The rescue of
lobulogenesis in the chimeric glands comprised of testicular
cells and PRKO MEC was incomplete compared to WT con-
trols, but was markedly increased above that seenwith PRKO-
LacZ cells alone, which failed to develop any mature lobules
[46].
As expected, mammary outgrowths derived from the inoc-
ulation of 5 × 104 PRKO-LacZ cells alone contained no PR+
epithelium in virgin or full-term pregnant mice [46]. However,
chimeric outgrowths derived from a mixture of 5 × 104
PRKO-LacZ MECs and 5 × 104 WT testicular cells contained
PR+ epithelium in both virgin as well as parturition mammary
outgrowths [46]. As the testicular derived cells are the only
cells with the capacity to express PR, these PR+ cells must be
derived from the redirected testicular cells [46]. It is clear from
these studies that PR signaling and lobulogenesis are not re-
quired for testicular cell reprogramming [46].
The studies described above suggest that occupation of
mammary niches by testicular cells during the initial ductal
growth results in the cellular reprogramming of the testicular
cells and does not require PR signaling [46]. Once in the
niche, these cells are redirected to a mammary epithelial cell
fate and can generate functional PR+ epithelial cells, which, in
turn, provide the signals necessary for lobulogenesis when P is
released during pregnancy [46]. We hypothesize that the ran-
dom occupation of niches by the testicular cells likely results
in the uneven distribution of PR+ epithelium in chimeric
glands, with clones generated from testicular-derived cells oc-
cupying the niche all expressing PR [46]. This uneven distri-
bution may account for the lack of complete lobulogenesis
seen in many chimeric glands [46]. The presence of PR+ cells
throughout the chimeric glands suggest that some testicular
cells are at least equally efficient at occupying reforming
mammary niches as endogenous mammary epithelial cells
[46]. While previous studies demonstrated that redirected
non-mammary cells contributed to lobulogenesis and milk
production, we now show that lobular development from
MECs and the signaling produced during this development
is not required for the reprogrammed cells to adopt these cel-
lular functions [46].
Review of the literature revealed several papers and re-
views on hormone signaling, growth factors, and their effect
on mammary cell populations and neoplasia [25, 47–50]. Two
recent papers show that steroid hormone signaling increases
the content of cells found in the BMammary Stem Cells^
(MaSC) fluorescent activated cell sorted (FACS) fraction
[51, 52]. For greater detail on progesterone signaling and its
effects on stem/progenitor cells, we direct the reader to the
review article by Hilton and Clarke included in this issue.
Prolactin
Prolactin Signaling in the Mammary Gland
Prolactin (Prl) is a 23 kDa protein that is mainly expressed by
the anterior pituitary gland. As a circulating hormone, Prl has
different functions depending on the targeted tissue or organ.
However, there are multiple extra pituitary Blocal^ sources of
Prl throughout the body, including the mammary epithelium
[53–56]. Smaller peptide fragments of the full length Prl have
been identified but their biological functions are unknown
[57]. As previously reviewed, the full length Prl can be sub-
jected to different post-translational modifications (splicing,
glycosylation, phosphorylation, deamination, sulfation) [58].
It is still to be determined whether suchmodifications can lead
to different biological Prl functions [59].
In the mammary gland, Prl is present both as a circulating
pituitary-derived as well as an epithelium-derived hormone.
Prl signaling has mitogenic, mammotropic and lactogenic
functions in mammary gland development. In mammary cells,
Prl binds to the cytokine cell surface Prl Receptor (PrlR) and
activates the Jak2/Stat5, Map Kinase, and PI3K-Akt signaling
pathways [57, 60, 61]. The PrlR exists in different spliced
isoforms (short and long) in both the mouse and humans that
share a common ligand and extracellular domain but differ in
the intracellular domain [62]. It is unknown whether Prl bind-
ing to different PrlR isoforms leads to activation of different
signaling pathways and thus different cellular responses to Prl
signaling.
Genetically engineered mouse models where either the tar-
get gene was deleted in the germ line or was conditionally
deleted demonstrated that Prl/PrlR/Jak2/Stat5 signaling stim-
ulates mammary epithelial differentiation that is necessary for
complete and functional lactation development of the mouse
mammary gland [53, 63–68]. Upon Prl binding to PrlR, the
Jak2/Sta5 signaling pathway is activated and the phosphory-
lated transcription factor Stat5 translocates to the nucleus
where it regulates the transcription of alveolar differentiation,
cell junctions and milk protein genes [66].
The TGF-β signaling, known for its function to inhibit
proliferation and differentiation of mammary epithelial cells,
has been shown to be a potent inhibitor of Prl signaling as well
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[69, 70]. A recent study identified the Ski family member
SnoN as the protein that regulates the interaction between
TGF-β and Prl signaling in mammary alveologenesis [71].
Recent findings have highlighted the importance of Prl
function during mammary gland development as an
epithelium-secreted factor. Using recombined mammary
gland tissue transplantation techniques Naylor et al. identified
autocrine Prl function in the mammary epithelium as indis-
pensable for the proliferation of mammary epithelial cells at
lactation [72]. It was recently shown that the PI3K-Akt sig-
naling pathway regulates autocrine expression of mammary
epithelium-derived Prl [61]. The recent study by Chen et al.
demonstrated that Akt interaction is followed by Stat5 activa-
tion and leads to mammary cell differentiation [61].
The luminal epithelium component of the mammary gland
is mainly composed of two types of epithelial cells: the hor-
mone sensing cells that express ER-α, PR, and PrlR and the
secretory cells characterized by the expression of Elf5 and the
ability to secrete milk upon hormonal stimuli from the neigh-
boring hormonal sensing cells. The progesterone target gene
RANKL has been identified as the proliferation paracrine fac-
tor, secreted upon Stat5 activation signaling pathway, between
the hormone sensing cells and the secretory cells that express
the receptor RANK [73]. It has been previously reported that
Prl paracrine signaling acts both directly and indirectly on
both secretory and hormone sensing cell populations [57,
74]. By this model, Prl, when present in low amounts, binds
to PrlR on the cell surface of hormone sensing cells, activates
Jak2/Stat5 signaling which leads to RANKL expression and
secretion [57]. The secreted RANKL then simulates the near
secretory cells to proliferate and differentiate. When Prl is
present in high concentration, it can directly bind to the PrlR
on secretory cells, activates Stat5 and the expression of the
differentiation marker Elf5. Overall, these studies demonstrate
that Prl/PrlR signaling in the mammary gland is indispensable
for lobulo-alveolar differentiation and milk secretion and
proper lactation.
Prolactin Regulates the Differentiation and Expansion
of Alveolar Cells During Mouse Mammary Gland
Development
Circulating hormone Prl can function as a proliferation and
differentiation factor of human mesenchymal stem cells, mouse
neural, hematopoietic and oligodendrocyte cells (for a review
see [75]). In the mammary gland, PrlR null (PrlRKO) mamma-
ry epithelium failed to develop milk secretory acini that filled
the fat pad when transplanted in the epithelium-divested fat pad
of Prl wild type (WT) mice [66, 76]. These studies were instru-
mental in identifying the importance of Prl signaling in mam-
mary epithelial cell differentiation.
In order to specifically identify whether mammary
epithelium-derived Prl plays a role in mammary gland
development, PrlKO tissue fragments were transplanted in
RAG1 KO mice that were bred and sacrificed at parturition
[72]. In this study, PrlKO mammary outgrowths showed full
lactation development [72]. A decrease in cell proliferation
rate was found in a subset of the PrlKO mammary outgrowths
at the onset of lactation [72]. The authors proposed that at the
onset of lactation a Bswitch mechanism^ occurs between en-
docrine and the mammary-epithelium Prl that in turn sustains
mammary cell proliferation [72].
As previously discussed, it is not known whether Prl sig-
naling stimulates the expansion of alveolar progenitors from
stem or multipotent ancestor cells or the expansion and differ-
entiation of alveolar progenitors into secretory cells [75]. It
was previously found that Prl signaling in the mammary gland
is not essential to mammary ductal elongation and expansion
during puberty [53, 63]. These results suggest that Prl signal-
ing does not regulate the expansion and/or differentiation of
mammary ductal cells with stem/progenitor ability during
puberty.
Recombined tissue transplantation experiments showed
the ability of any portion and of any developmental stage
of the mouse mammary gland to regenerate a full and
functional mammary outgrowth in vivo [77]. These results
demonstrated that existence of cell subpopulations with
stem/multipotent and/or progenitor functions in the adult
mammary tissues [77]. It is thought that during gland
regeneration in vivo, MEC come together with the exo-
genous cell populations and cells with stem/progenitors
capability contribute to the formation of mammary niches
where the different cell subpopulations complement each
other and redirect the expansion and differentiation of
exogenous cells.
As mentioned in the above section, Progesterone
Receptor (PR) null cells were mixed with WC/R26-lacZ+
testicular cells in an effort to identify what components of
the niche are necessary for redirection of exogenous cells
to a mammary cells fate. It was found that the autocrine/
paracrine progesterone signaling in the mammary epithe-
lium, necessary for ductal branching, is not indispensable
to redirect testicular cells to a mammary epithelium
phenotype [46].
Similar to studies by Bruno et al., PrlKO epithelial cells
were mixed with WC/R26-lacZ+ testicular cells and injected
into the cleared fat pad of athymic female PrlWT mice to
identify mammary epithelium-associated Prl function during
redirection of non-mammary cells by the mammary niche
(unpublished data). These unpublished results suggest that
mammary autocrine Prl signaling, like progesterone sig-
naling, is not necessary for the formation of a mammary
niche competent for the expansion of mammary stem/
progenitor cells and further support the conclusion that
the redirection process probably takes place before or
during ductal elongation [46].
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Conclusion
Our studies suggest that mammotropic hormones, their recep-
tors, and growth factors, although important to glandular
growth and development, are not required for signaling non-
mammary cells from mouse tissue to acquire a mammary cell
fate. Further, the redirected cells are committed to mammary
cell fates as they are able to self-renew, proliferate to contrib-
ute progeny in second-generation outgrowths, and to supply
the signaling component that is missing in the genetically
manipulated mammary cell population.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Schofield RThe relationship between the spleen colony-forming cell
and the haemopoietic stem cell. Blood Cells. 1978;4(1–2):7–25.
2. Bruno RD, Smith GH. Reprogramming non-mammary and cancer
cells in the developing mouse mammary gland. Semin Cell Dev
Biol. 2012;23(5):591–8. doi:10.1016/j.semcdb.2012.03.007.
3. Boulanger CA, Mack DL, Booth BW, Smith GH. Interaction with
the mammary microenvironment redirects spermatogenic cell fate
in vivo. Proc Natl Acad Sci U S A. 2007;104(10):3871–6. doi:10.
1073/pnas.0611637104.
4. Boulanger CA, Wagner KU, Smith GH. Parity-induced mouse
mammary epithelial cells are pluripotent, self-renewing and sensi-
tive to TGF-beta1 expression. Oncogene. 2005;24(4):552–60. doi:
10.1038/sj.onc.1208185.
5. Booth BW, Mack DL, Androutsellis-Theotokis A, McKay RD,
Boulanger CA, Smith GH. The mammary microenvironment alters
the differentiation repertoire of neural stem cells. Proc Natl Acad
Sci U S A. 2008;105(39):14891–6. doi:10.1073/pnas.0803214105.
6. Klinowska TC, Alexander CM, Georges-Labouesse E, Van der
Neut R, Kreidberg JA, Jones CJ, et al. Epithelial development
and differentiation in the mammary gland is not dependent on alpha
3 or alpha 6 integrin subunits. Dev Biol. 2001;233(2):449–67. doi:
10.1006/dbio.2001.0204.
7. Boulanger CA, Smith GH. Reprogramming cell fates in the mam-
mary microenvironment. Cell Cycle. 2009;8(8):1127–32.
8. Boulanger CA, Bruno RD, Rosu-Myles M, Smith GH. The mouse
mammary microenvironment redirects mesoderm-derived bone
marrow cells to a mammary epithelial progenitor cell fate. Stem
Cells Dev. 2012;21(6):948–54. doi:10.1089/scd.2011.0148.
9. Boulanger CA, Bruno RD, Mack DL, Gonzales M, Castro NP,
Salomon DS, et al. Embryonic stem cells are redirected to non-
tumorigenic epithelial cell fate by interaction with the mammary
microenvironment. PLoS One. 2013;8(4):e62019. doi:10.1371/
journal.pone.0062019.
10. Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signal-
ing: convergence of genomic and nongenomic actions on target
genes. Mol Endocrinol. 2005;19(4):833–42. doi:10.1210/me.
2004-0486.
11. Ali S, Coombes RC. Endocrine-responsive breast cancer and strat-
egies for combating resistance. Nat Rev Cancer. 2002;2(2):101–12.
doi:10.1038/nrc721.
12. ClemonsM, Goss P. Estrogen and the risk of breast cancer. N Engl J
Med. 2001;344(4):276–85. doi:10.1056/NEJM200101253440407.
13. Castoria G, Migliaccio A, Giovannelli P, Auricchio F. Cell prolif-
eration regulated by estradiol receptor: therapeutic implications.
Steroids. 2010;75(8–9):524–7. doi:10.1016/j.steroids.2009.10.007.
14. Levin ER.Minireview: extranuclear steroid receptors: roles in mod-
ulation of cell functions. Mol Endocrinol. 2011;25(3):377–84. doi:
10.1210/me.2010-0284.
15. Korach KS, Couse JF, Curtis SW,Washburn TF, Lindzey J, Kimbro
KS, et al. Estrogen receptor gene disruption: molecular characteri-
zation and experimental and clinical phenotypes. Recent Prog
Horm Res. 1996;51:159–86 discussion 86-8.
16. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF,
et al. Generation and reproductive phenotypes of mice lacking es-
trogen receptor beta. Proc Natl Acad Sci U S A. 1998;95(26):
15677–82.
17. Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach
KS, et al. Stromal estrogen receptors mediate mitogenic effects of
estradiol on uterine epithelium. Proc Natl Acad Sci U S A.
1997;94(12):6535–40.
18. Mallepell S, Krust A, Chambon P, Brisken C. Paracrine signaling
through the epithelial estrogen receptor alpha is required for prolif-
eration and morphogenesis in the mammary gland. Proc Natl Acad
Sci U S A. 2006;103(7):2196–201. doi:10.1073/pnas.0510974103.
19. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK,
Asselin-Labat ML, et al. Generation of a functional mammary
gland from a single stem cell. Nature. 2006;439(7072):84–8. doi:
10.1038/nature04372.
20. Kordon EC, Smith GH. An entire functional mammary gland may
comprise the progeny from a single cell. Development.
1998;125(10):1921–30.
21. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC,
Eaves CJ, et al. Steroid hormone receptor status of mouse mamma-
ry stem cells. J Natl Cancer Inst. 2006;98(14):1011–4. doi:10.1093/
jnci/djj267.
22. Potten CS, HumeWJ, Reid P, Cairns J. The segregation of DNA in
epithelial stem cells. Cell. 1978;15(3):899–906.
23. Smith GH. Label-retaining epithelial cells in mouse mammary
gland divide asymmetrically and retain their template DNA strands.
Development. 2005;132(4):681–7. doi:10.1242/dev.01609.
24. Booth BW, Smith GH. Estrogen receptor-alpha and progesterone
receptor are expressed in label-retaining mammary epithelial cells
that divide asymmetrically and retain their template DNA strands.
Breast Cancer Res: BCR. 2006;8(4):R49. doi:10.1186/bcr1538.
25. Clarke RB, Spence K, Anderson E, Howell A, OkanoH, Potten CS.
A putative human breast stem cell population is enriched for steroid
receptor-positive cells. Dev Biol. 2005;277(2):443–56. doi:10.
1016/j.ydbio.2004.07.044.
26. Zeps N, Bentel JM, Papadimitriou JM, D'Antuono MF, Dawkins
HJ. Estrogen receptor-negative epithelial cells in mouse mammary
gland development and growth. Differentiation; Res Biol Divers.
1998;62(5):221–226. doi:10.1046/j.1432-0436.1998.6250221.x.
27. Ciarloni L, Mallepell S, Brisken C. Amphiregulin is an essential
mediator of estrogen receptor alpha function in mammary gland
development. Proc Natl Acad Sci U S A. 2007;104(13):5455–60.
doi:10.1073/pnas.0611647104.
28. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A,
et al. Targeted inactivation of the EGF and amphiregulin genes
reveals distinct roles for EGF receptor ligands in mouse mammary
gland development. Development. 1999;126(12):2739–50.
29. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC,
Werb Z. Mammary ductal morphogenesis requires paracrine acti-
vation of stromal EGFR via ADAM17-dependent shedding of
J Mammary Gland Biol Neoplasia (2015) 20:93–101 99
epithelial amphiregulin. Development. 2005;132(17):3923–33. doi:
10.1242/dev.01966.
30. Booth BW, Boulanger CA, Anderson LH, Jimenez-Rojo L, Brisken
C, Smith GH. Amphiregulin mediates self-renewal in an immortal
mammary epithelial cell line with stem cell characteristics. Exp Cell
Res. 2010;316(3):422–32. doi:10.1016/j.yexcr.2009.11.006.
31. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H,
et al. Two distinct estrogen-regulated promoters generate transcripts
encoding the two functionally different human progesterone recep-
tor forms A and B. EMBO J. 1990;9(5):1603–14.
32. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely
OM. Subgroup of reproductive functions of progesterone mediated
by progesterone receptor-B isoform. Science. 2000;289(5485):
1751–4.
33. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM.
Defective mammary gland morphogenesis in mice lacking the pro-
gesterone receptor B isoform. Proc Natl Acad Sci U S A.
2003;100(17):9744–9. doi:10.1073/pnas.1732707100.
34. Conneely OM, Jericevic BM, Lydon JP. Progesterone receptors in
mammary gland development and tumorigenesis. J Mammary
Gland Biol Neoplasia. 2003;8(2):205–14.
35. Haslam SZ, Shyamala G. Relative distribution of estrogen and pro-
gesterone receptors among the epithelial, adipose, and connective
tissue components of the normal mammary gland. Endocrinology.
1981;108(3):825–30. doi:10.1210/endo-108-3-825.
36. Haslam SZ. The ontogeny of mouse mammary gland responsive-
ness to ovarian steroid hormones. Endocrinology. 1989;125(5):
2766–72. doi:10.1210/endo-125-5-2766.
37. Ismail PM, Amato P, Soyal SM, DeMayo FJ, Conneely OM,
O'Malley BW, et al. Progesterone involvement in breast develop-
ment and tumorigenesis–as revealed by progesterone receptor
Bknockout^ and Bknockin^ mouse models. Steroids. 2003;68(10–
13):779–87.
38. Ismail PM, Li J, DeMayo FJ, O'Malley BW, Lydon JP. A novel
LacZ reporter mouse reveals complex regulation of the progester-
one receptor promoter during mammary gland development. Mol
Endocrinol. 2002;16(11):2475–89. doi:10.1210/me.2002-0169.
39. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR,
Montgomery CA, Jr. et al. Mice lacking progesterone receptor
exhibit pleiotropic reproductive abnormalities. Genes Dev.
1995;9(18):2266–2278.
40. Humphreys RC, Lydon JP, O'Malley BW, Rosen JM. Use of PRKO
mice to study the role of progesterone in mammary gland develop-
ment. J Mammary Gland Biol Neoplasia. 1997;2(4):343–54.
41. Satoh K, Hovey RC, Malewski T, Warri A, Goldhar AS, Ginsburg
E, et al. Progesterone enhances branching morphogenesis in the
mouse mammary gland by increased expression of Msx2.
Oncogene. 2007;26(54):7526–34. doi:10.1038/sj.onc.1210555.
42. Robinson GW, Hennighausen L, Johnson PF. Side-branching in the
mammary gland: the progesterone-Wnt connection. Genes Dev.
2000;14(8):889–94.
43. Fernandez-Valdivia R, Mukherjee A, Ying Y, Li J, Paquet M,
DeMayo FJ, et al. The RANKL signaling axis is sufficient to elicit
ductal side-branching and alveologenesis in the mammary gland of
the virgin mouse. Dev Biol. 2009;328(1):127–39. doi:10.1016/j.
ydbio.2009.01.019.
44. Brisken C, Park S, Vass T, Lydon JP, O'Malley BW, Weinberg RA.
A paracrine role for the epithelial progesterone receptor in mamma-
ry gland development. Proc Natl Acad Sci U S A. 1998;95(9):
5076–81.
45. Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK,
et al. Essential function of Wnt-4 in mammary gland development
downstream of progesterone signaling. Genes Dev. 2000;14(6):
650–4.
46. Bruno RD, Boulanger CA, Rosenfield SM, Anderson LH, Lydon
JP, Smith GH. Paracrine-rescued lobulogenesis in chimeric
outgrowths comprising progesterone-receptor-null mammary epi-
thelium and redirected wild-type testicular cells. J Cell Sci.
2014;127(Pt 1):27–32. doi:10.1242/jcs.140749.
47. Axlund SD, Sartorius CA. Progesterone regulation of stem and
progenitor cells in normal and malignant breast. Mol Cell
Endocrinol. 2012;357(1–2):71–9. doi:10.1016/j.mce.2011.09.021.
48. Lydon JP. Stem cells: cues from steroid hormones. Nature.
2010;465(7299):695–6. doi:10.1038/465695a.
49. Brisken C, Hess K, Jeitziner R. Progesterone and overlooked endo-
crine pathways in breast cancer pathogenesis. Endocrinology.
2015;en20151392. doi:10.1210/en.2015-1392.
50. Joshi PA, Waterhouse PD, Kannan N, Narala S, Fang H, Di Grappa
MA, et al. RANK signaling amplifies WNT-responsive mammary
progenitors through R-SPONDIN1. Stem Cell Rep. 2015;5(1):31–
44. doi:10.1016/j.stemcr.2015.05.012.
51. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson
ER, et al. Control of mammary stem cell function by steroid hor-
mone signalling. Nature. 2010;465(7299):798–802. doi:10.1038/
nature09027.
52. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA,
Clarke CL, et al. Progesterone induces adult mammary stem cell
expansion. Nature. 2010;465(7299):803–7. doi:10.1038/
nature09091.
53. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M,
Nakashima K, Engle SJ, et al. Defective mammopoiesis, but nor-
mal hematopoiesis, in mice with a targeted disruption of the pro-
lactin gene. EMBO J. 1997;16(23):6926–35. doi:10.1093/emboj/
16.23.6926.
54. Steinmetz RW, Grant AL, Malven PV. Transcription of prolactin
gene in milk secretory cells of the rat mammary gland. J
Endocrinol. 1993;136(2):271–6.
55. Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND. Prolactin
gene-disruption arrests mammary gland development and retards
T-antigen-induced tumor growth. Oncogene. 2000;19(8):1077–84.
doi:10.1038/sj.onc.1203348.
56. Fields K, Kulig E, Lloyd RV. Detection of prolactin messenger
RNA in mammary and other normal and neoplastic tissues by po-
lymerase chain reaction. Lab Invest; J Tech Methods Pathol.
1993;68(3):354–360.
57. HorsemanND, Gregerson KA. Prolactin actions. J Mol Endocrinol.
2014;52(1):R95–106. doi:10.1530/JME-13-0220.
58. Sinha YN. Structural variants of prolactin: occurrence and physio-
logical significance. Endocr Rev. 1995;16(3):354–69. doi:10.1210/
edrv-16-3-354.
59. Bachelot A, Binart N. Reproductive role of prolactin.
Reproduction. 2007;133(2):361–9. doi:10.1530/REP-06-0299.
60. Das R, Vonderhaar BK. Activation of raf-1, MEK, andMAP kinase
in prolactin responsive mammary cells. Breast Cancer Res Treat.
1996;40(2):141–9.
61. Chen CC, Stairs DB, Boxer RB, Belka GK, HorsemanND, Alvarez
JV, et al. Autocrine prolactin induced by the Pten-Akt pathway is
required for lactation initiation and provides a direct link between
the Akt and Stat5 pathways. Genes Dev. 2012;26(19):2154–68. doi:
10.1101/gad.197343.112.
62. Trott JF, Hovey RC, Koduri S, Vonderhaar BK. Alternative splicing
to exon 11 of human prolactin receptor gene results in multiple
isoforms including a secreted prolactin-binding protein. J Mol
Endocrinol. 2003;30(1):31–47.
63. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H,
et al. Null mutation of the prolactin receptor gene produces multiple
reproductive defects in the mouse. Genes Dev. 1997;11(2):167–78.
64. Shillingford JM, Miyoshi K, Robinson GW, Grimm SL, Rosen JM,
Neubauer H, et al. Jak2 is an essential tyrosine kinase involved in
pregnancy-mediated development of mammary secretory epitheli-
um. Mol Endocrinol. 2002;16(3):563–70. doi:10.1210/mend.16.3.
0805.
100 J Mammary Gland Biol Neoplasia (2015) 20:93–101
65. Wagner KU, Krempler A, Triplett AA, Qi Y, George NM, Zhu J,
et al. Impaired alveologenesis and maintenance of secretory mam-
mary epithelial cells in Jak2 conditional knockout mice. Mol Cell
Biol. 2004;24(12):5510–20. doi:10.1128/MCB.24.12.5510-5520.
2004.
66. Miyoshi K, Shillingford JM, Smith GH, Grimm SL, Wagner KU,
Oka T, et al. Signal transducer and activator of transcription (Stat) 5
controls the proliferation and differentiation of mammary alveolar
epithelium. J Cell Biol. 2001;155(4):531–42. doi:10.1083/jcb.
200107065.
67. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D,
Wang D, et al. Stat5a and Stat5b proteins have essential and nonessen-
tial, or redundant, roles in cytokine responses. Cell. 1998;93(5):841–50.
68. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA,
et al. Requirement of STAT5b for sexual dimorphism of body
growth rates and liver gene expression. Proc Natl Acad Sci U S
A. 1997;94(14):7239–44.
69. Moses H, Barcellos-Hoff MH. TGF-beta biology in mammary de-
velopment and breast cancer. Cold Spring Harb Perspect Biol.
2011;3(1):a003277. doi:10.1101/cshperspect.a003277.
70. Jhappan C, Geiser AG, Kordon EC, Bagheri D, Hennighausen L,
Roberts AB, et al. Targeting expression of a transforming growth
factor beta 1 transgene to the pregnant mammary gland inhibits
alveolar development and lactation. EMBO J. 1993;12(5):1835–45.
71. Jahchan NS, Wang D, Bissell MJ, Luo K. SnoN regulates mamma-
ry gland alveologenesis and onset of lactation by promoting
prolactin/Stat5 signaling. Development. 2012;139(17):3147–56.
doi:10.1242/dev.079616.
72. Naylor MJ, Lockefeer JA, Horseman ND, Ormandy CJ. Prolactin
regulates mammary epithelial cell proliferation via autocrine/
paracrine mechanism. Endocrine. 2003;20(1–2):111–4. doi:10.
1385/ENDO:20:1-2:111.
73. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA,
et al. The osteoclast differentiation factor osteoprotegerin-ligand is
essential for mammary gland development. Cell. 2000;103(1):
41–50.
74. Brisken C, Ayyanan A, Doppler W. Prolactin signaling and Stat5:
going their own separate ways? Breast Cancer Res: BCR.
2002;4(6):209–12.
75. Shemanko CS.Mammary epithelial stem and progenitor cells and the
prolactin pathway. Front Biosci: J Virtual Libr. 2008;13:3940–3950.
76. Brisken C, Kaur S, Chavarria TE, Binart N, Sutherland RL,
Weinberg RA, et al. Prolactin controls mammary gland develop-
ment via direct and indirect mechanisms. Dev Biol. 1999;210(1):
96–106. doi:10.1006/dbio.1999.9271.
77. Smith GH, Medina D. A morphologically distinct candidate for an
epithelial stem cell in mouse mammary gland. J Cell Sci.
1988;90(Pt 1):173–83.
J Mammary Gland Biol Neoplasia (2015) 20:93–101 101
